Disease Detection and Prevention: Synthetic Biology's Impact on Diagnostics at SynbioBeta's Biopharma Day
One of the easiest (and fastest) ways of stopping disease is to detect it before it starts. During 2020, several synthetic biology companies offered novel was to rapidly diagnose COVID19. Synthetic biology offers rational and systematic approaches to building highly accurate diagnostics devices. In this session, we'll explore the state of synbio diagnostics, lessons from the COVID19 pandemic, as well as future outlook.

Helene Steiner will be joined by:

Rahul Dhanda
CEO, Sherlock Biosciences

Sri Kosuri
CEO, Octant Bio

Janice Chen
Co-founder & CTO
Mammoth Biosciences